361 related articles for article (PubMed ID: 11719463)
1. Transgenic Polyoma middle-T mice model premalignant mammary disease.
Maglione JE; Moghanaki D; Young LJ; Manner CK; Ellies LG; Joseph SO; Nicholson B; Cardiff RD; MacLeod CL
Cancer Res; 2001 Nov; 61(22):8298-305. PubMed ID: 11719463
[TBL] [Abstract][Full Text] [Related]
2. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
4. Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis.
Al Masri A; Gendler SJ
Oncogene; 2005 Sep; 24(38):5799-808. PubMed ID: 15897873
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice.
Kirma N; Gill K; Mandava U; Tekmal RR
Cancer Res; 2001 Mar; 61(5):1910-8. PubMed ID: 11280746
[TBL] [Abstract][Full Text] [Related]
6. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
7. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
[TBL] [Abstract][Full Text] [Related]
9. Mammary tumorigenesis and metastasis in transgenic mice.
Webster MA; Muller WJ
Semin Cancer Biol; 1994 Feb; 5(1):69-76. PubMed ID: 8186390
[TBL] [Abstract][Full Text] [Related]
10. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice.
Zhang H; Kuang SQ; Liao L; Zhou S; Xu J
Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215
[TBL] [Abstract][Full Text] [Related]
11. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
Yoshidome K; Shibata MA; Couldrey C; Korach KS; Green JE
Cancer Res; 2000 Dec; 60(24):6901-10. PubMed ID: 11156389
[TBL] [Abstract][Full Text] [Related]
12. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.
Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA
Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133
[TBL] [Abstract][Full Text] [Related]
15. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
16. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice.
Sevenich L; Werner F; Gajda M; Schurigt U; Sieber C; Müller S; Follo M; Peters C; Reinheckel T
Oncogene; 2011 Jan; 30(1):54-64. PubMed ID: 20818432
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ.
Namba R; Maglione JE; Young LJ; Borowsky AD; Cardiff RD; MacLeod CL; Gregg JP
Mol Cancer Res; 2004 Aug; 2(8):453-63. PubMed ID: 15328372
[TBL] [Abstract][Full Text] [Related]
18. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
[TBL] [Abstract][Full Text] [Related]
20. Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes.
Maglione JE; McGoldrick ET; Young LJ; Namba R; Gregg JP; Liu L; Moghanaki D; Ellies LG; Borowsky AD; Cardiff RD; MacLeod CL
Mol Cancer Ther; 2004 Aug; 3(8):941-53. PubMed ID: 15299077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
